- Home
- FUN vs SRRK Comparison
FUN vs SRRK Comparison
Compare FUN & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUN
- SRRK
- Stock Information
- Founded
- FUN 1983
- SRRK 2012
- Country
- FUN United States
- SRRK United States
- Employees
- FUN N/A
- SRRK N/A
- Industry
- FUN Services-Misc. Amusement & Recreation
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FUN Consumer Discretionary
- SRRK Health Care
- Exchange
- FUN Nasdaq
- SRRK Nasdaq
- Market Cap
- FUN 4.7B
- SRRK 4.2B
- IPO Year
- FUN 1987
- SRRK 2018
- Fundamental
- Price
- FUN $48.62
- SRRK $44.78
- Analyst Decision
- FUN Strong Buy
- SRRK Strong Buy
- Analyst Count
- FUN 14
- SRRK 7
- Target Price
- FUN $56.07
- SRRK $40.43
- AVG Volume (30 Days)
- FUN 1.5M
- SRRK 1.3M
- Earning Date
- FUN 02-13-2025
- SRRK 11-12-2024
- Dividend Yield
- FUN 1.23%
- SRRK N/A
- EPS Growth
- FUN N/A
- SRRK N/A
- EPS
- FUN 0.37
- SRRK N/A
- Revenue
- FUN $2,392,739,000.00
- SRRK N/A
- Revenue This Year
- FUN $84.75
- SRRK N/A
- Revenue Next Year
- FUN $3.91
- SRRK N/A
- P/E Ratio
- FUN $133.07
- SRRK N/A
- Revenue Growth
- FUN 33.41
- SRRK N/A
- 52 Week Low
- FUN $35.93
- SRRK $6.76
- 52 Week High
- FUN $58.70
- SRRK $46.19
- Technical
- Relative Strength Index (RSI)
- FUN 61.79
- SRRK 67.23
- Support Level
- FUN $45.26
- SRRK $40.22
- Resistance Level
- FUN $48.41
- SRRK $44.22
- Average True Range (ATR)
- FUN 1.70
- SRRK 2.80
- MACD
- FUN -0.10
- SRRK -0.30
- Stochastic Oscillator
- FUN 91.80
- SRRK 84.04
About FUN Cedar Fair L.P.
Six Flags Entertainment Corp is North America's regional amusement-resort operator with 27 amusement parks, 15 water parks and nine resort properties across 17 states in the U.S., Canada and Mexico. Six Flags provides coasters, themed rides, thrilling water parks, resorts and a portfolio of beloved intellectual property such as Looney Tunes, DC Comics and PEANUTS.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.